Drug Treatment of Functional Dyspepsia

References

• Talky N J., Phillips S F. Nonulcer dyspepsia: potential causes and pathophysiology. Ann Intern Med 1988; 108: 865–879
   PubMedGoogle Scholar
• Colin‐Jones D G., Bloom B, Bodemar G, et al. Management of dyspepsia: report of a working party. Lancet 1988; 1: 576–579
   PubMed Web of Science ®Google Scholar
• Drossman D A., Thompson W G., Talley N J., Funch‐Jensen P, Janssens J, Whitehead W. Identification of subgroups of functional gastrointestinal disorders. Gastroenterol Int 1990; 3: 159–172
   Google Scholar
• Joelsson B, Johnson F. Heartburn—the acid test. Gut 1989; 30: 1523–1528
   PubMed Web of Science ®Google Scholar
• Klauser A G., Schindlbeck N, Müller‐Lissner S A. Symptoms in gastrooesophageal reflux disease. Lancet 1990; 335: 205–208
   PubMed Web of Science ®Google Scholar
• Klein K. Controlled treatment trials in the irritable bowel syndrome: a critique. Gastroenterology 1988; 95: 232–241
   PubMed Web of Science ®Google Scholar
• Talley N J., McNeil D, Hayden A, Colreavy C, Piper D W. Prognosis of chronic unexplained dyspepsia. A prospective study of potential predictor variables in patients with endosmotically diagnosed non‐ulcer dyspepsia. Gastroenterology 1987; 92: 1060–1066
   PubMed Web of Science ®Google Scholar
• Veldhuyzen S JO, Tytgat K MAJ, Jali S, Goodacre R L., Hunt R H. Can gastritis symptoms be evaluated in clinical trials? An overview of treatment of gastritis, non‐ulcer dyspepsia and Campylobacter‐associated gastritis. J Clin Gastroenterol 1989; 11: 496–501
   PubMedGoogle Scholar
• Camilleri M, Malagelada J R., Kao P C., Zinsmeister A R. Gastric and autonomic responses to stress in functional dyspepsia. Dig Dis Sci 1986; 31: 1169–1177
   PubMed Web of Science ®Google Scholar
• Malagelada J R., Stanghellini V. Manometric evaluation of functional upper gut symptoms. Gastroenterology 1985; 88: 1223–1231
   PubMed Web of Science ®Google Scholar
• Johnson A G. Controlled trial of metoclopramide in the treatment of flatulent dyspepsia. Br Med J 1971; 2: 25–26
   PubMed Web of Science ®Google Scholar
• De Loose F. Domperidone in chronic dyspepsia: a pilot open study and a multi centre general practice crossover comparison with metoclopramide and placebo. Pharmatherapeutica 1979; 2: 140–146
   Google Scholar
• Perkel M S., Moore C, Hersh T, Davidson E D. Metoclopramide therapy in patients with delayed gastric emptying: a randomized, double‐blind study. Dig Dis Sci 1979; 24: 662–666
   PubMed Web of Science ®Google Scholar
• Orme M LE, Tallis R C. Metoclopramide and tardive dyskinesia in the elderly. Br Med J 1984; 289: 397–398
   PubMedGoogle Scholar
• Champion M C. Domperidone. Gen Pharmacol 1988; 19: 499–505
   PubMedGoogle Scholar
• Weihrauch T R., Forster C RF, Krieglstein J. Evaluation of the effect of domperidone on human esophageal and gastroduodenal motility by intra‐luminal manometry. Post grad Med J 1979; 55: 7
   PubMedGoogle Scholar
• Valenzuela D M. Effects of domperidone on the symptoms of reflux esophagitis. R SOC Med Int Cong Symp Series 1981; 36: 51–57
   Google Scholar
• Baeyens R, Reyntjens A, Van de Velde E. Effects of domperidone (R33812) on the motor function of the stomach and small intestine. Arzneimittelforsch 1978; 28: 682
   PubMedGoogle Scholar
• De Schepper A, Wollaert F, Reyntjens A. Effects of oral domperidone on gastric emptying and motility. Arzneimittelforsch 1978; 28: 1196
   PubMed Web of Science ®Google Scholar
• Van Ganse W, Van Damme L, Van de Mierop L, Deruyttere M, Lauwers W, Coenegrachts J. Chronic dyspepsia: double‐blind treatment with domperidone (R33812) or a placebo. A multi‐centre therapeutic evaluation. Curr Ther Res 1978; 23: 695–701
   Google Scholar
• Arts E, C H., de Roy G, D'Hollander J, Verhaegen H. Domperidone in the treatment of dyspepsia: a double‐blind placebo‐controlled study. J Int Med Res 1979; 7: 158–161
   PubMedGoogle Scholar
• Van de Mierop L, Rutgeerts L, Van den Langen‐bergh B, Staessen A. Oral domperidone in chronic postprandial dyspepsia. A double‐blind placebo‐controlled evaluation. Digestion 1979; 19: 244–250
   PubMed Web of Science ®Google Scholar
• Haarmann K, Lebkuchner F, Widmann A, Kief W, Esslinger M. A double‐blind study of domperidone in the symptomatic treatment of chronic postprandial upper gastrointestinal distress. Postgrad Med J 1979; 55(suppl 1)24–27
   PubMedGoogle Scholar
• Bekhti A, Rutgeerts L. Domperidone in the treatment of functional dyspepsia in patients with delayed gastric emptying. Postgrad Med J 1979; 55(suppl l)30–32
   PubMedGoogle Scholar
• Englert W, Schlich D. A double‐blind crossover trial of domperidone in chronic postprandial dyspepsia. Postgrad Med J 1979; 55(suppl l)28–29
   PubMedGoogle Scholar
• Nagler J, Miskovitz P. Clinical evaluation of domperidone in the treatment of chronic postprandial idiopathic upper gastrointestinal distress. Am J Gastroenterol 1981; 76: 495–499
   PubMedGoogle Scholar
• Agorastos I, Zissis N P., Kaprinis I, Goulis G. Double‐blind evaluation of domperidone in acute vomiting and dyspeptic disorders. J Int Med Res 1981; 9: 143–147
   PubMedGoogle Scholar
• Sarin S K., Sharma P, Chawla Y K., Gopinath P, Nundy S. Clinical trial on the effect of domperidone on non‐ulcer dyspepsia. Indian J Med Res 1986; 83: 623–628
   PubMed Web of Science ®Google Scholar
• Davis R H., Clench M H., Mathias J R. Effects of domperidone in patients with chronic unexplained upper gastrointestinal symptoms: a double‐blind, placebo‐controlled study. Dig Dis Sci 1988; 33: 1505–1511
   PubMed Web of Science ®Google Scholar
• Hui W M., Lam S K., Lok A SF, Ng M MT, Wong K L., Fok K H. Sulpiride improves functional dyspepsia: a double‐blind controlled study. J Gastroenterol Hepatol 1986; 1: 391–399
   Google Scholar
• McCallum R W., Prakash C, Campoli‐Richards D M., Goa K L. Cisapride. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use as a prokinetic agent in gastrointestinal motility disorders. Drugs 1988; 36: 652–681
   PubMed Web of Science ®Google Scholar
• Ceccatelli P, Janssens J, Vantrappen G, Cucchiara S. Cisapride restores the decreased lower oeso‐phageal sphincter pressure in reflux patients. Gut 1988; 29: 631–635
   PubMedGoogle Scholar
• Gilbert R J., Dodds W J., Kahrilas P J., Hogan W J., Lipman S. Effect of c, a new prokinetic agent, on esophageal motor function. Dig Dis Sci 1987; 32: 1331–1336
   PubMedGoogle Scholar
• Smout A JPM, Bogaard J W., Grade A C., et al. Effects of cisapride, a new gastrointestinal prokinetic substance, on interdigestive and post‐pyramidal motor activity of the distal esophagus in man. Gut 1985; 26: 246–251
   PubMedGoogle Scholar
• Madsen J L. Effects of cisapride on gastrointestinal transit in healthy humans. Dig Dis Sci 1990; 35: 1500–1504
   PubMedGoogle Scholar
• Camilleri M, Brown M L., Malagelada J R. Impaired transit of chyme in chronic intestinal pseudo‐obstruction. Correction by cisapride. Gastro‐enterology 1986; 92: 619–626
   Google Scholar
• Horowitz M, Maddox A, Harding P E., et al. Effect of cisapride on gastric and oesophageal emptying in insulin‐dependent diabetes mellitus. Gastroenterology 1987; 93: 1899–1907
   Google Scholar
• Feldman M, Smith H J. Effect of cisapride on gastric emptying of indigestible solids in patients with gahtroparesis diabeticorum. A comparison with metoclopramide and placebo. Gastroenterology 1986; 92: 171–171
   Google Scholar
• T'estoni P A., Bagnolo F, Fanti L, Passaretti S, Tittobello A. Longterm oral cisapride improves interdigestive antroduodenal motility in dyspeptic patients. Gut 1990; 31: 286–290
   PubMedGoogle Scholar
• Schuurkes J AJ, Helsen L FM, Ghoos E CR, Eelen J GM, Van Nueten J M. Stimulation of gastroduodenal motor activity: cccand cholinergic modulation. Drug Develop Res 1986; 8: 233–141
   Google Scholar
• Moriarty K J., Higgs N B., Woodford M, Warhurst G, Turnberg L A. Inhibition of the effect of serotonin oil rat ileal transport by cisapride: evidence in hour of the involvement of 5–HT2 receptors. Gut 1987; 28: 844–848
   PubMedGoogle Scholar
• Creytens G. Effect of the non‐antidopaminergic drug cisapride on postprandial nausca. Curr Ther Res 1984; 36: 1063–1069
   Google Scholar
• Milo K. Non‐cholinergic. non‐antidopaminergic treatment of chronic digestive symptoms suggestive of a motility disorder: a two‐step pilot evaluation of ciqridc. Curr Ther Res 1984; 36: 1053–1062
   Google Scholar
• Creytens G. Control of reflux symptoms in hiatal‐hernia patients through stimulation of gastric ocsophageal motility with cisapride. Pragr Med 1987; 43(Suppl 1)35–41
   Google Scholar
• Rösch W. Cisapride in non‐ulcer dyspepsia. Results of a placebo‐controlled trial. Scand J Gastroenterol 1987; 22: 161–164
   PubMed Web of Science ®Google Scholar
• Coutant G, François I, DeNutte N, DeCock G, Horger P, Rutgcerts L. Dose rcsponse study of eisapride in the management of non‐ulcer dyspepsia. Progr Med 1987; 43(suppl 1)91–96
   Google Scholar
• Van Gansc W, Reyntjens A. Clinical evaluation of cisapride in postprandial dyspepsia. Progr Med 1987; 43(suppl 1)77–81
   Google Scholar
• Corinaldesi R, Stanghellini V, Raiti C, Rea E, Salgemini R, Barbara L. Effect of chronic administration of cisapride on gastric emptying of a solid meal and on dyspeptic symptoms in patients with idiopathic gastroparesis. Gut 1987; 28: 300–305
   PubMed Web of Science ®Google Scholar
• Goethals C. Van DeMierop L. Cisapride in the treatment of chronic functional dyspepsia. Results of a double‐blind, placebo controlled, crossover study. Curr Ther Res 1987; 42: 261–!67
   Google Scholar
• Franclois I, DeNutte N. Non‐ulcer dyspepsia. Effect of the gastrointestinal prokinetic drug cisapride. Curr Ther Res 1987; 41: 891–898
   Google Scholar
• Hannon R. Efficacy of cisapride in patients with non‐ulcer dyspepsia. A placebo‐controlled study. Curr Ther Res 1987; 42: 814–822
   Google Scholar
• Deruyttere M, Milo R, Creytens G, Goethals C, Bourgeois E, Offner E. Therapy of chronic functional dyspepsia: multicenter crossover study of cisapride and placebo. Progr Med 1987; 43(suppl 1)61–68
   Google Scholar
• Corinaldesi R, Raiti C, Stanghellini V, et al. Comparative effects of oral cisapride and metoclopramide on gastric emptying of solids and symptoms in patients with functional dyspepsia and gastroparesis. Curr Ther Res 1987; 42: 428–435
   Web of Science ®Google Scholar
• Verhaegen H, De Cree J, Leempoels J. Treatment of chronic dyspepsia with eisapride and domperi‐done. Acta Ther 1987; 13: 38.5–394
   Google Scholar
• Jian R, Ducrot F, Ruskone A, et al. Symptomatic radionuclide and therapeutic assessment of chronic idiopathic dyspepsia: a double‐blind placebo‐controlled evaluation of cisapride. Dig DisSci 1989; 34: 657–664
   PubMed Web of Science ®Google Scholar
• DeNutte N, Van Ganse W, Wetterbulghe M, De France P. Relief of epigastric pain in non‐ulcer dyspepsia: controlled trial of the promotility drug cisapride. Clin Ther 1989; 11: 62–68
   PubMedGoogle Scholar
• Van Outryve M, Van Eeghem P, Reyntjens A (1990) Cisapride in the treatment of non‐ulcer dyspepsia patients, unresponsive to domperidone or metoclopramide: a multi centre, double‐blind, placebo‐controlled study [Abstract]. Abstract Book. World Congresses of Gastroenterology, SydneyAustralia, August, 1990. The Medicine Group (UK) Ltd., Abingdon, FP628
   Google Scholar
• Gaddum J H., Picarelli Z P. Two kinds of tryptamine receptor. Br J Pharmacol 1957; 12: 323–328
   PubMed Web of Science ®Google Scholar
• Peroutka S J., Snyder S H. Multile serotonin receptors: differential binding of [3 H]5–hydroxy‐tryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. Mol Pharmacol 1979; 16: 687–699
   PubMed Web of Science ®Google Scholar
• Dumis A, Bouhelal R, Sebben M, Cory R, Bockaert J. A non classical 5–hydroxytryptamine receptor positively coupled with adenylate cyclase in the central nervous system. Mol Pharmacol 1983; 34: 880
   Google Scholar
• Kilpatrick G J., Jones B J., Tycrs M B. Identification and distribution of 5–HT3 receptors in rat brain using radioligand binding. Nature 1987; 330: 746–748
   PubMed Web of Science ®Google Scholar
• Fozard J R., Mobarok A, Newgrosh G. Blockage of serotonin receptors on autonomic neurones by (‐)‐cocaine and some related compounds. Eur J Pharmacol 1979; 59: 195–210
   PubMedGoogle Scholar
• Fozard J R. Neuronal 5–HT receptors in the periphery. Neuro pharmacology 1984; 23: 1473–1486
   Google Scholar
• Richardson B P., Engel G, Donatsch P, Stadler P A. Identification of serotonin M‐receptor subtypes and their specific blockage by a new class of drugs. Nature 1986; 316: 126–131
   Google Scholar
• Hesketh P J., Murphy W K., Lester E P., et al. GR 38032F (GR‐C507/75): a novel compound effective in the prevention of acute cisplatin‐induced emesis. J Clin Oncol 1989; 7: 700–705
   PubMed Web of Science ®Google Scholar
• Jones B J., Oakley N R., Tyers M B. The anxiolytic activity of GR 38032F, a 5–HT3 receptor antagonist, in the rat and cynomolgus monkey. Br J Pharmacol 1987; 90: 88P
   Google Scholar
• Akkermans L MA, Vos A, Hoekstra A, Roelofs J MM, Horowitz M. Effect of ICS 205–930 (a specific 5HT3 receptor antagonist) on gastric emptying of a solid meal in normal subjects. Gut 1988; 29: 1229–1252
   PubMedGoogle Scholar
• Meleagros L, Kreymann B, Ghatei M A., Bloom S R. Mouth‐to‐cecum transit time in man is reduced by a novel serotonin M‐receptor antagonist [Abstract]. Gut 1987; 28: A1373
   Web of Science ®Google Scholar
• Talley N J., Phillips S F., Haddad A, et al. Effect of a 5HT3 antagonist (GR 38032F) on small intestinal transit and release of gastrointestinal peptides. Dig Dis Sci 1989; 34: 1511–1515
   PubMed Web of Science ®Google Scholar
• Gore S, Gilmore I T., Haigh C G., Brown less S M., Stockdale H, Morris A I. Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5–hydroxytryptamine receptor (type 3) antagonist. Aliment Pharmacol Ther 1990; 4: 139–144
   PubMed Web of Science ®Google Scholar
• Itoh Z, Nakaya M, Suzuki T, Arai H, Wakabayashi K. Erythromycin mimics exogenous motilin in gastrointestinal contractile activity in the dog. Am J Physiol 1984; 247: G688–G694
   Google Scholar
• Kondo Y, Torii K. Itoh 2. Omura S. Erythromycin and its derivatives with motilin‐like biological activities inhibit the specific binding of 125I‐motilin to duodenal muscle. Biochem Biophys Res Commun 1988; 150: 877–882
   PubMed Web of Science ®Google Scholar
• Janssens J, Peeters T L., Vantrappen G, et al. Improvement of gastric emptying in diabetic gastro‐paresis by erythromycin. Preliminary studies. N Engl J Med 1990; 322: 1028–1031
   PubMed Web of Science ®Google Scholar
• Reynolds J C. Prokinetic agents: a key in the future of gastroenterology. Gastroenterol Clin North Am 1989; 18: 437–457
   PubMed Web of Science ®Google Scholar
• Farrell R L., Rolling F T., Castell D O. Stimulation of incompetent lower esophageal sphincter. A possible advantage in therapy of chronic heartburn. Am J Dig Dis 1973; 18: 646–650
   PubMedGoogle Scholar
• McCallum R W., Kline M M., Curry N, et al. Comparative effects of metodopramide and hethanechol on lower esophageal sphincter pressure in reflux patients. Gastroenterology 1975; 68: 1114–1118
   PubMedGoogle Scholar
• Phaeosawasdi K, Malmud L S., Tolin R D., et al. Cholinergic effects on esophageal transit and clearance. Gastroenterology 1981; 81: 915–920
   PubMedGoogle Scholar
• Cohen S, Green F. Force‐velocity characteristics of esophageal muscle: effect of acetylcholine and nor epinephrine. Am J Physiol 1974; 226: 1250–1255
   PubMedGoogle Scholar
• McCallum R W. Review of the current status of prokinetic agents in gastroenterology. Am J Gastroenterol 1985; 80: 1008–1016
   PubMed Web of Science ®Google Scholar
• Kragen G, Huddleston L, Wollstonecraft P. Comparison of dicyclomine with antacids and without antacids in dyspepsia. J Int Med Res 1984; 12: 174–178
   PubMedGoogle Scholar
• Walters J M., Crean P, McCarthy C F. Trimebutine, a new antispasmodic in the treatment of dyspepsia. Irish J Med 1980; 73: 380–381
   PubMedGoogle Scholar
• Stephens C JM, Lever L, Hoare A M. Dicyclomine for idiopathic dyspepsia. Lancet 1988; 1: 1004
   PubMedGoogle Scholar
• Nørrelund N, Helles A, Schmiegelow M. Ukaraktäristisk dyspepsi i almen praksis. En kontrolleret undersøgelse med et antacidum (Aliminoxè). Ugeskr Laeger 1980; 142: 1750–1753
   PubMedGoogle Scholar
• Nyrén O, Adami H ‐O, Bates S, et al. Absence of therapeutic benefit from antacids or cimetidine in non‐ulcer dyspepsia. N Engl J Med 1986; 314: 339–343
   PubMed Web of Science ®Google Scholar
• Gotthard R, Bodemar G, Brodin U, Jöjnsson K ‐A. Treatment with cimetidine, antacid or placebo in patients with dyspepsia of unknown origin. Scand J Gastroenterol 1988; 23: 7–18
   PubMed Web of Science ®Google Scholar
• Weberg R, Berstad A. Low‐dose antacids and pirenzepine in the treatment of patients with non‐ulcer dyspepsia and erosive prepyloric changes. A randomized, double‐blind, placebo‐controlled trial. Scand J Gastroenterol 1988; 23: 237–243
   PubMed Web of Science ®Google Scholar
• La Brooy S, Lovell D, Misiewicz J J. The treatment of non‐ulcer dyspepsia. Cimetedine. The Westminster Hospital Symposium, C Wastell, P Lance. Churchill Livingstone, London 1978; 131–140
   Google Scholar
• Bendtsen F, Danø P, Guldhammer B, Remvig L, Krogsøe O. ccc of røntgennegativ dyspepsi. Ugeskr Laeger 1983; 145: 3090–3093
   PubMedGoogle Scholar
• Kelbaek F, Linde J, Eriksen J, Munkgaard S, Moesgaard F, Bonnevie O. Controlled clinical trial of treatment with cimetidine for non‐ulcer dyspepsia. Acta Med Scand 1985; 217: 281–287
   PubMed Web of Science ®Google Scholar
• Lance P, Wastell C, Schiller K FR. A controlled trial of cimetidine for the treatment of non‐ulcer dyspepsia. J Clin Gastroenterol 1986; 8: 414–418
   PubMed Web of Science ®Google Scholar
• Olubuyide I O., Ayoola E A., Okubanjo A O., Atoba M A. Non‐ulcer dyspepsia in Nigerians clinical and therapeutic results. Scand J Gastroenterol 1986; 21(suppl 124)83–87
   Google Scholar
• Mackinnon M, Willing R L., Whitehead R. Cimetidine in the management of symptomatic patients with duodenitis. A double‐blind controlled trial. Dig Dis Sci 1982; 27: 217–219
   PubMed Web of Science ®Google Scholar
• Nesland A A., Berstad A. Effect of cimetidine in patients with non‐ulcer dyspepsia and erosive prepyloric changes. Scand J Gastroenterol 1985; 20: 629–635
   PubMed Web of Science ®Google Scholar
• Delattre M, Malesky M, Prinzie A. Symptomatic treatment of non‐ulcer dyspepsia with cimetidine. Curr Ther Res 1985; 37: 980–991
   Web of Science ®Google Scholar
• Talley N J., McNeil D, Hayden A, Piper D W. Randomized. double‐blind. placebo‐controlled crossover trial of cimetidine and pirenzepine in non‐ulcer dyspepsia. Gastroenterology 1986; 91: 149–156
   PubMed Web of Science ®Google Scholar
• Johannessen T, Fjøsne U, Kleveland P M., et al. Cimetidine responders in non‐ulcer dyspepsia. Scand J Gastroenterol 1988; 23: 327–336
   PubMed Web of Science ®Google Scholar
• Singal A K., Kumar A, Broor S L. Cimetidine in the treatment of non‐ulcer dyspepsia: results of a randomized double‐blind, placebo‐controlled study. Curr Med Res Opin 1989; 11: 390–397
   PubMed Web of Science ®Google Scholar
• Saunders J HB, Oliver R J., Higson D L. Dyspepsia: incidence of non‐ulcer disease in a controlled trial of ranitidine in general practice. Br Med J 1986; 292: 665–668
   PubMed Web of Science ®Google Scholar
• Dal Monte P R., D'Imperio N, Accardo P, Daniotti S. Pirenzepine in non‐ulcer dyspepsia. A double‐blind, placebo controlled trial. Scand J Gastroenterol 1983; 17(suppl 72)247–250
   Google Scholar
• Hradsky M, Wikander M. Effect of pirenzepine in the treatment of non‐ulcer dyspepsia. A double‐blind study. Scand J Gastroenterol 1983; 17(suppl 72)251–254
   Google Scholar
• Christiansen J, Aagaard P, Koudahl G. Truncal vagotomy and drainage in the treatment of ulcer‐like dyspepsia without ulcer. Acla Chir Scand 1973; 139: 173–175
   PubMedGoogle Scholar
• Aase S T., Liavag I, Roland M. Proxrmal vagotomy in dyspeptic patients without an ulcer. World J Surg 1984; 8: 303–307
   PubMedGoogle Scholar
• Kairaluoma M I., Hentilae R, Alavaikko M, et al. Sucralf ate versus placebo in treatment of non‐ulcer dyspepsia. Am J Med 1987; 83(suppl 3B)51–55
   PubMedGoogle Scholar
• Skoubo‐Kristensen E, Funch‐Jensen P, Kruse A, Hanberg‐Sbrensen F, Amdrup E. Controlled clinical trial with sucralfate in the treatment of macroscopic gastritis. Scand J Gastroenterol 1989; 24: 716–720
   PubMed Web of Science ®Google Scholar
• Talley N J. Is Helicobacter pylori a cause of nonulcer dyspepsia?. Helicobacter pylori. gastritis and peptic ulcer, P Malfertheiner, H Ditschuneit. Springer Verlag, Berlin 1990; 361–369
   Google Scholar
• McNulty C AM, Gearty J C., Crurnp B, et al. Campylobacter pyloridis and associated gastritis: investigator blind, placebo‐controlled trial of bismuth salicylate and erythromycin ethyl‐succinate. Br Med J 1986; 293: 645–649
   PubMed Web of Science ®Google Scholar
• Lambert J R., Borromeo M, Korman M G., Hansky J. Role of Campylobacter pyloridis in non‐ulcer dyspepsia ‐ a randomized controlled trial [Abstract]. Gastroenterology 1987; 92: 1488
   Web of Science ®Google Scholar
• Rokkas T, Pursey C, Uzoechina E, et al. Non‐ulcer dyspepsia and short‐term De‐Nol therapy: A placebo‐controlled trial with particular reference to the role of Campylobacter pylori. Gut 1988; 29: 1386–1391
   PubMed Web of Science ®Google Scholar
• Borody T, Hennessy W, Daskalopoulas G, Carrick J, Hazell S. Double‐blind trial of De‐Nol in non‐ulcer dyspepsia associated with Campylobacter pyloridis gastritis [Abstract]. Gastroenterology 1987; 92: 1324
   Web of Science ®Google Scholar
• Loffeld R JLF, Potters H VPJ, Stobberingh E, Flendrig J A., Van Spreeuwel J P., Arends J W. Campylobacter‐associated gastritis in patients with non‐ulcer dyspepsia: a double‐blind, placebo‐controlled trial with colloidal bismuth sub citrate. Gut 1989; 30: 1206–1212
   PubMed Web of Science ®Google Scholar
• Kang J Y., Tay H H., Wee A, Guan R, Math M V., Yap I. Effect of colloidal bismuth sub citrate on symptoms and gastric histology in non‐ulcer dyspepsia. A double‐blind, placebo‐controlled study. Gut 1990; 31: 476–480
   PubMed Web of Science ®Google Scholar
• Glupczynski Y, Burette A, Labbe M, Deprez C, De Reuck M, Deltenre M. Campylobacter pylori‐associated gastritis: A double‐blind placebo‐controlled trial with amoxycillin. Am J Gastroenterol 1988; 83: 365–372
   PubMed Web of Science ®Google Scholar
• Morgan D, Kraft W, Bender M, Pearson A. Nitrofurans in the treatment of gastritis associated with Campylobacter pylori. Gastroenterology 1988; 95: 1178–1184
   PubMed Web of Science ®Google Scholar
• Talley N J., Ormand J E., Carpenter H A., Phillips S F. Triple therapy for Helicobacter pylori in non‐ulcer dyspepsia. Am J Gastroenterol 1991; 86: 121–123
   PubMed Web of Science ®Google Scholar
• Dobrilla G, Comberlato M, Steele A, Vallaperta P. Drug treatment of functional dyspepsia. A meta‐analysis of randomized controlled trials. J Clin Gastroenterol 1989; 11: 169–177
   PubMed Web of Science ®Google Scholar